• Home
  • About
  • Leadership
  • Technology
  • Pipeline
  • News
  • Careers
  • Contact

Recent Posts

  • Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
  • Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
  • Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
  • Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition
  • Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Archives

  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • October 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • June 2020

Categories

  • Press Releases

Archives

  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • October 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • June 2020

Category: Advisors

Edith A. Perez, M.D.

Jae Park, M.D.

Richard Maziarz, M.D.

Evren Alici, M.D., Ph.D.

  • Privacy Policy
  • Terms

© Artiva Biotherapeutics, Inc., 2023

Sign up for news updates


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy